Connor, Clark & Lunn Investment Management (CC&L)’s NeoGenomics NEO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.7M	Sell	802,597 -135,455	-14%	-$1.31M	0.02%	501
2026 Q1	$6.96M	Buy	938,052 +60,103	+7%	+$632K	0.02%	583
2025 Q4	$10.3M	Buy	877,949 +318,643	+57%	+$3.44M	0.03%	460
2025 Q3	$4.32M	Buy	559,306 +489,846	+705%	+$3.43M	0.01%	624
2025 Q2	$508K	Buy	+69,460	New	+$561K	﹤0.01%	1252

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NEO Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its NeoGenomics (NEO) stake by 14% in Q2 2026, selling an estimated $1.31M and leaving 802,597 shares worth $11.7M. The position accounts for 0.02% of the portfolio, ranked #501.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NEO in Q2 2025 and has held it in 5 quarters since. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 802,597 shares of NeoGenomics worth $11.7M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 135,455 NeoGenomics shares in Q2 2026, an estimated $1.31M.
NeoGenomics made up 0.02% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #501 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NeoGenomics in Q2 2025 and has held it in 5 quarters since.
266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.